Normunity, a biotechnology company creating novel anti-cancer therapies, has closed a Series B financing round $75 million. The financing was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage University Partners, HSG (HongShan Capital Group), and Connecticut Innovations.

Proceeds from the financing will be used to advance Normunity’s lead programme, NRM‑823, a first-in-class T cell engager that binds a novel, highly specific tumour target expressed on multiple types of solid tumours. The company plans to initiate the Phase 1 clinical trial of NRM-823 in 2H 2025 and leverage its prior work by advancing other modalities against this tumour-specific target, including antibody‑drug conjugates and radiotheranostics.

The funding will also be used to advance Normunity’s pipeline of programmes that address novel targets responsible for tumour-specific immune suppression.